- Our view
- Unrated
- Price then
- INR 236.75
- Target
- Unrated
- Market cap then
- INR 2,713 Cr.
Fineotex Chemical Ltd. makes specialty chemicals for textiles, FMCG, cleaning and hygiene, and is entering oil & gas and water treatment. Minerva Capital Research Solutions assigns no rating or target price, but gives the company a Positive Outlook, citing capacity expansion and opportunities in new segments.
About Fineotex Chemical
Fineotex Group was established in 1979, and Fineotex Chemical Ltd. was incorporated in 2004. The company manufactures specialty chemicals, with over 470+ product categories and a focus on sustainable solutions. Its products serve textiles, FMCG, cleaning and hygiene, while it is stepping into oil & gas and water treatment. Manufacturing facilities in Maharashtra and Malaysia have current installed capacity of 104,000 MTPA.
Investment Rationale
- Broad product range and customer retention: Fineotex serves the textile value chain from cleaning and dyeing to printing and finishing, with over 1500+ SKUs across product categories. Management cited cost benefits and the ability to supply chemicals across the value chain as reasons customers stay.
- Capacity expansion: A 15,000 MTPA phase 1 addition at Ambernath is expected to start operations from Q2-FY26. The report estimates sales potential of INR 80-90 Cr. at realization of INR 72-80 / kg and peak utilization of 75%.
- Flexible facilities support new segments: Existing India facilities, with installed capacity ~97,500 MTPA, are fungible across current businesses and new oil & gas and water treatment segments. Standard Operating Procedures are in place for changeover between segments.
- Product development and customer additions: The company added 30 new customers in Q3FY25 in textiles and has strategic collaborations with HealthGuard, Australia and Eurodye CTC for new product introduction and distribution.
- Revenue diversification: Management sees potential for oil & gas and water treatment revenues together to outpace textile and FMCG revenues in 4 to 5 years. It also sees potential for Aquastrike Premium, a mosquito killer and water preservation additive, in India and overseas.
Fineotex Chemical Key Financials
| Particulars (INR Cr.) | FY24 (A) | FY25 (E) | FY26 (P) | FY27 (P) |
|---|---|---|---|---|
| Revenue | 569 | 590 | 721 | 887 |
| % Y-o-Y Growth | 10.1% | 3.6% | 22.2% | 23.1% |
| EBITDA % | 26.1% | 26.3% | 26.6% | 27.7% |
| PAT % | 20.7% | 22.2% | 21.6% | 22.8% |
| CFO / EBITDA % | 65.6% | 90.7% | 73.6% | 73.4% |
| ROE % | 26.7% | 21.2% | 16.8% | 17.1% |
Revenue estimates and ratios are attributed to 1 analyst.
Valuation and Target Price
Fineotex Chemical is Unrated and the report does not assign a target price. The report notes a target price of INR 366/- and revenue estimates from 1 analyst, sourced to S&P Capital IQ; this is not presented as Minerva Capital Research Solutions' target. The stated outlook for the company is Positive.
- INR 236.75
- CMP (02-Apr’25)
- Unrated
- Target price
- Positive
- Outlook
Management Meeting Takeaways
- Expected segment growth: Management expects growth of ~15% to 20% for textiles and ~10% to 15% for FMCG, cleaning & hygiene. The report cites industry growth estimates of ~5% CAGR for Indian textile chemicals from 2024 to 2033 and ~11% CAGR for FMCG household cleaners from 2025 to 2029.
- Capacity utilisation: Management considers peak capacity utilization of ~70% to 80% on a conservative basis to allow for changeovers between business segments.
- Fund raise and acquisition discussions: The company raised total INR 342.5 Cr. through equity shares and warrants in CY24; ~INR 192.5 Cr. was received and INR 150 Cr. was expected in Nov’25 and Jan’26 or H2-FY26. Discussions were in process for an overseas acquisition, which management said would be EPS accretive.
- Textile tariff impact: The report expects the Indian textile sector to benefit as a destination for US imports, citing tariffs of Vietnam:46%, Bangladesh:37%, China: 54%, Pakistan: 29%, Cambodia: 49% vs lower India tariffs: 26%.
Key Risks
- Competition: The company faces high competitive intensity from domestic and multinational companies, including DOW and BASF.
- Raw material exposure: Importing raw materials for finished goods creates dependency on China and exposure to raw material price volatility.
- Export markets: Export revenues may be affected by geopolitical tensions and internal government issues in Bangladesh.
- Execution and ramp-up: Capacity utilization at the upcoming 15,000 MTPA plant and revenues from oil & gas, water treatment and Aquastrike are monitorables.
Shareholding
| As on | 31-Dec’23 | 31-Mar’24 | 31-Dec’24 |
|---|---|---|---|
| Promoter | 65.04% | 65.03% | 62.87% |
| FII | 0.82% | 1.45% | 3.36% |
| DII | 3.69% | 3.70% | 3.61% |
| Other | 30.46% | 29.83% | 30.17% |
| Total | 100.00% | 100.00% | 100.00% |
Our View Fineotex Chemical
The report's Positive Outlook is based on the company's growth track record, improving margins, cash and bank balances, and prospective revenue from new segments. New capacity and diversification are the central opportunities, while competition, China-linked raw material exposure and the pace of new-segment growth remain important risks. Fineotex Chemical remains Unrated, with no Minerva target price assigned.
Standard disclosures
- Research Analyst has served as an officer, director or employee of subject company(ies): No
- We or our associates have received compensation from the subject company(ies) in the past 12 months: No
- We or our associates have managed or co-managed public offering of securities for the subject company(ies) in the past12 months: No
- We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months: No
- We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report: No
- We or our associates or Research Analyst or his/her relative's financial interest in the subject company(ies): No
- Nature of financial interest in subject company, if any: Nil
- We, our associates or Research Analyst have actual/beneficial ownership of 1% or more securities of the subject company (ies) at the end of the month immediately preceding the date of publication of R: No
- Subject company (ies) may have been client during twelve months preceding the date of distribution of the research report: No.
- We or our Associates or Research Analyst are engaged in market making of subject company: No
- By referring to any particular sector, Minerva Capital Research Solutions does not provide any promise or assurance of favorable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. Such representations are not indicative of future results.
- There are either no material conflict of interests or all existing and potential conflict of interest are disclosed herein.
Regulatory disclosures
Minerva Capital Research Solutions is an independent investment advisory firm founded by Nishant Gupta(SEBI registration no. INH000018896).
Registration granted by SEBI and certification from NISM in no way promise or guarantee that the research recommendation will provide any assured, minimum or risk-free return to the investors.
The research report serves as general information and does not account for individual investment goals, financial situations, or needs. Minerva Capital Research Solutions strives to provide reliable and comprehensive information, sourced from what are believed to be trustworthy channels. However, this information has not been independently verified by Minerva Capital Research Solutions or its analysts, and no guarantees are made regarding its accuracy or completeness. The opinions expressed in this report reflect the views of the research analyst at the time of publication and may change over time. Minerva Capital Research Solutions and its affiliates as on date of publication of this report does not hold any positions in the securities discussed. The views presented are general and do not consider individual risk tolerance or investment objectives; therefore, readers should seek independent professional advice before making investment decisions. Minerva Capital Research Solutions does not guarantee a favorable outlook for any specific industry or sector and urges investors to consider all relevant risk factors, including their financial circumstances, before investing. The analyst certifies that their views accurately represent their personal opinions on the companies discussed and that no part of their compensation is tied to specific recommendations made in this report. This material should not be interpreted as an offer or solicitation to buy or sell securities in jurisdictions where such offers would be illegal. Consequently, brokerage and investment services described herein are not available to Canadian or U.S. persons. Distribution outside India requires prior written consent. This Research Report assumes that the recipient will assume all risks associated with its contents. If there are any disagreements or dissatisfaction with this report or its disclaimer, the only recourse is to cease using it. Minerva Capital Research Solutions and its affiliates will not be liable for any direct or indirect losses resulting from the use of this report. Recipients are required to adhere to these restrictions. The material is for the personal use of authorized individuals and does not constitute a solicitation or offer to buy or sell any securities in jurisdictions where such actions would be illegal.
For any queries or grievances: Mr. Nishant Gupta | Email: nishant.gupta@mcapital.in | Contact Number: 8171433387 | Website: www.mcapital.in
Rating rationale
Minerva Capital Research Solutions endeavors to provide objective opinions and recommendations. Ratings are assigned to stocks according to their fair value vs current market price and then categorizes them as Buy, Hold, Reduce, Sell. The performance horizon is one year unless specified and fair value is defined as analyst’s valuation for a stock.
- Buy:> 15%
- Hold: -5% to 15%
- Reduce: -15% to -5%
- Sell: <-15%